Design of the Trial to Assess Chelation Therapy (TACT)

Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002.


TACT is an National Institutes of Health-sponsored, randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial testing the benefits and risks of 40 infusions of a multicomponent disodium EDTA chelation solution compared with placebo and of an oral, high-dose multivitamin and mineral supplement. TACT has randomized and will follow up 1,708 patients for an average of approximately 4 years. The primary end point is a composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. A 900-patient substudy will examine quality-of-life outcomes. The trial is designed to have >85% power to detect a 25% relative reduction in the primary end point for each treatment factor. Enrollment began in September 2003 and was completed in October 2010.

Trial registration: NCT00044213.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chelating Agents / administration & dosage
  • Chelating Agents / therapeutic use*
  • Chelation Therapy*
  • Complementary Therapies
  • Coronary Artery Disease / drug therapy*
  • Dietary Supplements
  • Double-Blind Method
  • Edetic Acid / adverse effects
  • Edetic Acid / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Minerals / administration & dosage
  • Research Design
  • Treatment Outcome
  • Vitamins / administration & dosage*


  • Chelating Agents
  • Minerals
  • Vitamins
  • Edetic Acid

Associated data